We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current VYGR market cap is 478.72M. The company's latest EPS is USD 2.4370 and P/E is 3.62.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 41.09M | -1.55M | 150.48M | 4.85M | 4.61M |
| Operating Income | 14.44M | -24.56M | 122.88M | -25.43M | -29.51M |
| Net Income | 17.62M | -23.63M | 124.04M | -22.21M | -25.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 104.39M | 171.13M | 37.42M | 40.91M | 250.01M |
| Operating Income | -51.68M | 27.38M | -73.62M | -50.84M | 122.01M |
| Net Income | -43.6M | 36.74M | -71.2M | -46.41M | 132.33M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 182.48M | 159.36M | 336.29M | 315.54M | 294.65M |
| Total Liabilities | 102.66M | 100.34M | 119.33M | 116.51M | 118.43M |
| Total Equity | 79.82M | 59.02M | 216.96M | 199.03M | 176.22M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 354.76M | 261.58M | 193.86M | 159.36M | 351.28M |
| Total Liabilities | 255.25M | 107.26M | 98.8M | 100.34M | 114.96M |
| Total Equity | 99.51M | 154.32M | 95.06M | 59.02M | 236.32M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -265k | -12.51M | 123.57M | 122.73M | 101.68M |
| Investing | -21.41M | -7.34M | 14.49M | -10.17M | -168.48M |
| Financing | 834k | 1.11M | 31.31M | 32.85M | 33.19M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 48.67M | -96.72M | -53.53M | -12.51M | 77.92M |
| Investing | -90.48M | 113M | 65.91M | -7.34M | -141.64M |
| Financing | 80.99M | 3.16M | 612k | 1.11M | 33.65M |
| Market Cap | 478.72M |
| Price to Earnings Ratio | 3.62 |
| Price to Sales Ratio | 1.91 |
| Price to Cash Ratio | 6.95 |
| Price to Book Ratio | 2.02 |
| Dividend Yield | - |
| Shares Outstanding | 54.3M |
| Average Volume (1 week) | 491.24k |
| Average Volume (1 Month) | 482.66k |
| 52 Week Change | 20.11% |
| 52 Week High | 14.3398 |
| 52 Week Low | 6.06 |
| Spread (Intraday) | 0.01 (0.11%) |
| Company Name | Voyager Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.voyagertherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
